Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Denali Therapeutics
Biotech
Biogen axes Denali-partnered Parkinson’s drug after phase 2 flop
The phase 2b Parkinson’s trial missed its primary endpoint, prompting the partners to end development in the idiopathic form of the condition.
Nick Paul Taylor
May 22, 2026 6:12am
Takeda tears up Denali partnership, returning dementia asset
Apr 6, 2026 1:50pm
Fierce Pharma
FDA approves Denali's Hunter syndrome drug
Mar 25, 2026 2:50pm
Sanofi keeps mum on Denali pact after scrapping final RIPK1 drug
Jan 29, 2026 5:16am
Denali ph. 1 Pompe plans hit with clinical hold
Dec 4, 2025 11:52am
Royalty's $275M financing deal for Denali drug awaiting FDA nod
Dec 4, 2025 10:20am
